Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ABS-201 IV Single Dose, ABS-201 Single Dose
ABS-201 · 1 trial · 2 indications
Safety assessments based on reporting of Treatment Emergent Adverse Events
| Arm | Type | Description |
|---|---|---|
| SAD IV Dose 1 - 150mg ABS201 or Placebo | EXPERIMENTAL | ABS-201 IV Single Dose |
| SAD IV Dose 2 - 450mg ABS201 or Placebo | EXPERIMENTAL | Single Intra-venous dose of active study drug or placebo in Healthy Volunteers |
| SAD IV Dose 3 - 900mg ABS201 or Placebo | EXPERIMENTAL | Single Intra-venous dose of active study drug or placebo in Healthy Volunteers |
| SAD IV Dose 4 - 1800mg ABS201 or Placebo | EXPERIMENTAL | Single Intra-venous dose of active study drug or placebo in Healthy Volunteers |
| MAD SC Dose 1 - 300mg ABS201 or Placebo | EXPERIMENTAL | Multiple Ascending Doses of active study drug or placebo delivered subcutaneously in Patients with AGA |
| MAD SC Dose 2 - 600mg ABS201 or Placebo | EXPERIMENTAL | Multiple Ascending Doses of active study drug or placebo delivered subcutaneously in Patients with AGA |
| MAD SC Dose 2 - 1200mg ABS201 or Placebo | EXPERIMENTAL | Multiple Ascending Doses of active study drug or placebo delivered subcutaneously in Patients with AGA |
| Name | Type | Description |
|---|---|---|
| ABS-201 IV Single Dose | DRUG | ABS-201 is an IgG1 monoclonal antibody developed to specifically target the prolactin receptor (PRLR), |
| Placebo IV | DRUG | Matching placebo |
| ABS-201 SC Multiple Doses | DRUG | Multiple doses of ABS-201 for Subcutaneous injection |
| Placebo SC Injection | DRUG | Subcutaneous Placebo injection for MAD arms |
Inclusion Criteria (Major): * Participants must be overtly healthy, as determined by medical evaluation, which includes a review of medical and surgical history, physical examination, and a 12-lead ECG. * Must have normal ranges for hematology, clinical chemistry, coagulation tests, and urine analy...
ABS-201 Single Dose is an investigational small molecule being developed for androgenetic alopecia (AGA), a common form of hair loss. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in healthy adults with and without AGA.
ABS-201 Single Dose is being developed by Absci Corporation, a biopharmaceutical company traded on the stock exchange under the ticker symbol ABSI. The company is conducting clinical trials to evaluate the safety and tolerability of this investigational drug for androgenetic alopecia.
ABS-201 Single Dose is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The ongoing Phase 1 trial is recruiting participants to evaluate single and multiple ascending doses in healthy adults.
ABS-201 Single Dose is being evaluated in a Phase 1 clinical trial registered as NCT07317544. This randomized, double-blind, controlled study is recruiting 227 participants in Australia to assess single and multiple ascending doses in healthy adults with and without androgenetic alopecia.
Yes, ABS-201 Single Dose is also known as ABS-201 IV Single Dose. Both names refer to the same investigational drug being developed by Absci Corporation for the treatment of androgenetic alopecia. The drug is administered intravenously and is currently in Phase 1 clinical trials.